Summary: Losartan, a selective angiotensin receptor antagonist, is mainly metabolized by CYP2C9 to an active carboxylic acid, E3174, which is pharmacologically more potent inhibitor than the parent compound. We evaluated the effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan and E3174, which were measured by high performance liquid chromatography in human volunteers and rats. A randomized crossover design study with two phases was done in the volunteer study. In the first phase, the volunteers received losartan 25 mg alone orally (LOS group), and, in the second phase, losartan 25 mg was given after repeated oral administration of 300 mg bucolome for 7 days (LOS＋BUC group). In the LOS group, the maximum concentration (Cmax) and area under the concentration curve (AUC) of losartan were significantly higher than in the LOS＋BUC group. On the other hand, in the LOS＋BUC group, the C max and AUC of E3174 were significantly lower than in the LOS group. In the rat study, male Wistar ST rats were used. In the first phase, the rats orally received losartan 10 mg/kg alone or after bucolome was given repeatedly at a dose of 20, 50, or 200 mg/kg for 7 days. In the second phase for steady state, the rats were given losartan 10 mg/kg for 14 days (group A) or losartan 10 mg/kg and bucolome 50 mg/kg for 14 days (Group B). Bucolome at doses 50 and 200 mg/kg significantly increased the AUC losartan and significantly decreased the AUC of 3174. At the steady state, there were no significant differences in AUC of losartan between Group A and B, but the Cmax and AUC of E3174 were significantly lower in Group B than Group A.
Introduction
Losartan (LOS) is a selective angiotensin receptor antagonist that is used in the treatment of hypertension and heart failure. 1) LOS is mainly metabolized to an active carboxylic acid, E3174, which is a more potent inhibitor at the angiotensin II subtype 1 receptor, showing a greater area under the concentration-time curve (AUC) and a longer half-life than LOS. 2, 3) The conversion of LOS to E3174 is mainly catalyzed by cytochrome P450 (CYP) 2C9. 4) Bucolome (BUC) is used as a non-steroidal anti-inflammatory drug (therapeutic dose, 600-1200 mg/day) or as a uricosuric agent (therapeutic dose, 300-1200 mg/day). It is a CYP2C9 inhibitor, equipotent to phenylbutazone and sulfinpyrazone. [5] [6] [7] Therefore, it is suggested that when LOS and CYP2C9 inhibitors are given concomitantly, the bioavailability of E3174 is decreased; leading theoretically to decreases the pharmacodynamic effects of LOS. In this study, to evaluate the potential drug interaction between LOS and CYP2C9 inhibitors, the effects of BUC on the pharmacokinetics of LOS and E3174 were studied in healthy human volunteers and rats.
Method
Materials: LOS and E3174 were supplied by Merck Co. Ltd.. Bumetanide and carboxymethyl cellulose sodium salt were purchased from Wako Pure Chemical Industries Ltd. (Osaka Japan). Acetonitrile used in high-performance liquid chromatography (HPLC) was of reagent grade. The other reagents were also of reagent grade and were used without further purification.
Volunteer Study: Six male volunteers (mean age, 25.2 years; age range, 21-34 years; mean weight, 62.3 kg; weight range, 56.0-70.0 kg) were enrolled in this study after their written informed consents were obtained. The study was approved by the Ethics Committee of Niigata University of Pharmacy and Applied Life Sciences. The subjects were healthy based on physical examinations, medical histories, and routine laboratory studies. They had no evidence of clinically significant renal, hepatic, cardiac, gastrointestinal, hematologic, central nervous system, or other chronic diseases.
The study had a randomized crossover design with two treatment phases, which was separated by a 7-day washout period separated the two treatment phases. Each volunteer received one tablet (25 mg) of LOS potassium orally at 08:00 with 200 mL water. In the first phase, the volunteers received LOS potassium alone (LOS group); in the second phase, LOS potassium was given after repeated administration of BUC 300 mg one orally at 08:00 for 7 days (LOS＋ BUC group). Each volunteer was fasted overnight for at least 10 hours before being given LOS potassium and was further fasted for additional 6 hours. The subjects were instructed not to take any medications or to drink alcoholic beverages for 1 week prior to and during the study.
Blood samples were drawn just before and 1, 2, 4, 6, 9, 12, and 24 hours after LOS potassium was given. Approximately 5 mL of blood was collected each time from a cubital vein using a disposal syringe into a vacuum blood collection tube. The samples were centrifuged within 1 hour after collection, and the harvested serum was frozen at -209 C until.
Rat Study: Twenty-four male Wistar ST rats (age, 8 weeks; mean weight, 234 g; weight range, 200-265 g) were kept in an animal room with a 12-hour light-dark cycle (light on at 06:00). The rats were purchased from Japan SLC (Shizuoka, Japan). The animal experimental plan used has been approved by the Committee of Laboratory Animal Center, and conforms to the Guiding Principles for the Care and Use of Experimental Animals in Niigata University of Phrmacy and Applied Life Sciences. They were divided into 6 groups, with 4 rats in each group. The rats were fasted overnight for at least 10 hours overnight before LOS potassium while they were allowed free access to water. All experiments were carried out at a room temperature of 24 ±19 C.
Single dose study: In the first phase, LOS potassium 10 mg/kg was given to rats orally (LOS(Control)). In the second phase, LOS potassium 10 mg/kg was given orally to rats after repeated administration of BUC 20 mg/kg (LOS＋ 20BUC), 50 mg/kg (LOS＋50BUC), or 200 mg/kg (LOS＋ 200BUC) once daily for 7 days. For these experiments, LOS potassium and BUC were dissolved in a solution containing 1% carboxymethyl cellulose sodium salt.
Long-term study: Clinically, ntihypertensive agents, such as losartan, is administered for long-term. Therefore, the effects of the BUC on the pharmacokinetics of LOS and E3174 at steady-state were studied. In the first phase, LOS potassium 10 mg/kg was given orally to rats for 14 days (Group A). In the second phase, LOS potassium 10 mg/kg and BUC 50 mg/kg were given concomitantly for 14 days (Group B). Blood samples were taken just before and 1, 2, 4, 6, 8, and 10 hours after the last dose of LOS potassium. Each blood sample, approximately 0.3 mL was collected directly from the jugular vein using a disposable syringe and then transferred to a heparinized tube. The samples were centrifuged, and the harvested plasma was frozen at -209 C until analysis.
LOS Assay: Concentrations of LOS and E3174 in human serum and rat plasma were determined based on a slightly modified HPLC technique using bumetanide as an internal standard substance (IS). 8, 9) In brief, LOS and E3174 were extracted with diethylether and the organic layer was evaporated to dryness. To 1.0 mL of human serum or 0.1 mL of rat plasma, 100 mL of 5 mg/mL IS was added and 500 mL or 50 mL of 0.01 M hydrochloric acid were added. LOS and E3174 were extracted twice each with 5 mL of diethylether and the organic layer was evaporated to dryness. The residue was reconstituted using 200 mL of the mobile phase for HPLC. Then 50 mL of this solution was injected into the HPLC system equipped with a reversed phasecolumn (Shim-pack CLC-ODS (M), 4.6 mm in inside diameter and 250 mm in length. Shimadzu, Kyoto, Japan) and a spectrofluorometric detector with excitation/emission wavelength set at 250/370 nm.
The mobile phase consisting of a mixture of 10 mmol/L phosphate buffer solution at pH 2.3 and acetonitrile (60:40 [vol/vol]) was used at a flow rate of 1.0 mL/min. The retention times of LOS, E3174, and IS were 8.9, 15.2 and 19.4 min., respectively. The limit of quantification was 5 ng/mL for both LOS and E3174. Inter-and intra-day assay variations were less than 5%.
Pharmacokinetic and Statistical analysis: The maximum concentration of LOS and E3174 in the serum or plasma (Cmax) and the time to reach Cmax (tmax) were obtained directly from the concentration data. The area under the serum or plasma concentration-time curve from zero to the last sampling time (AUC0-10 or 24) was calculated using the linear trapezoidal rule. Data were expressed as mean±stan-dard deviation (SD). The statistical analysis was done using Student's t-test. All statistical analyses were performed with Microsoft Office Excel 2003 software (Microsoft, Redmond, WA). Values of pº0.05 were considered statistically significant.
Results
Volunteer study: The serum concentration-time profiles of LOS and E3174 in healthy volunteers after LOS potassium 25 mg was given with or without preceding con- comitant repeated administration of BUC 30 mg once daily for 7 days are shown in Figure 1 . The pharmacokinetic parameters are shown in Table 1 . The Cmax and AUC0-24 of LOS in the LOS＋BUC group were significantly higher than those in the LOS group. On the other hand, the Cmax and AUC0-25 of E3174 in the LOS＋BUC group were significantly lower than those in the LOS group. These results indicate that the metabolism of LOS to E3174 was markedly inhibited by BUC given concomitantly. Rat study: In Figure 2 , the dose of bucolome was plotted against the AUC of LOS and E3174 in the single study, where LOS was administered at a single dose of 10 mg/kg and BUC was administered repeatedly at a dose of 20, 50 or 200 mg/kg once daily for 7 days. The pharmacokinetic parameters are shown in Table 2 . As shown in Figure 2 , the AUC of LOS increased with the dose of BUC, while AUC of E3174 decreased. The Cmax and AUC0-10 of LOS in BUC-treated rats at 50 and 20 mg/kg were significantly higher than those in control rats. On the other hand, the Cmax and AUC0-10 of E3174 in the BUC-treated rats at 50 and 200 mg/kg were significantly lower than those in control rats.
The plasma concentration-time profiles of LOS and E3174 in the long-term study, where LOS at a dose of 10 mg/kg with or without BUC at a dose of 50 mg/kg were administered repeatedly once daily for 14 days, are shown in Figure 3 , and the pharmacokinetic parameters are shown in Table 3 . No significant differences were observed in the AUC0-10 of LOS between Group A, which was treated with LOS alone, and Group B, which was treated with LOS and BUC together, but the Cmax and AUC0-10 of E3174 in Group B were significantly lower than those in Group A.
Discussion
As shown in Table 1 , in the volunteer study, the conversion of LOS to E3174 was significantly decreased when BUC was given concomitantly. Table 2 shows that, in the rat single study, AUC of LOS was significantly increased by BUC somehow in a dose-dependent manner at dose of 50 and 200 mg/kg, although the magnitude of the interaction by BUC was not much different between 50 and 200 mg/kg. The conversion of LOS to E3174 is mainly catalyzed by CYP2C9 in humans. 4) BUC is a CYP2C9 inhibitor, as the effect of BUC on the metabolic clearance of (S)-warfarin, which is mainly metabolized by CYP2C9, 5) is known to be equivalent to those of phenylbutazone and sulfinpyrazone.
5-7)
Rats do not have the CYP isoforms orthologous to human CYP2C9. However, the isoforms of rats having very similar enzymatic properties to CYP2C9 would be involved in the metabolic clearance of LOS in rats, thus causing a drug interaction of LOS and BUC in this animal species.
As shown in Table 3 , the pharmacokinetic parameters of LOS were not much affected when BUC 50 mg/kg was given concomitantly for 14 days to rats. However, the AUC of E3174 was significantly decreased by concomitant administration of BUC. The oral bioavailability of LOS is 33%, and the extent of conversion of LOS to E3174 by in humans is approximately 14% (presystemic 8.0%, systemic 5.6%) of the oral or intravenous dose.
2)
In addition to conversion to E3174 by CYP2C9, LOS has other metabolic pathways, which would be catalyzed by other CYP isoforms or enzymes. [12] [13] [14] [15] These results suggest that the decreased bioavailability of E3174, while unaffected bioavailability of LOS by concomitant administration of BUC is a consequence of the decreased conversion of LOS to E3174 by the CYP2C9 inhibition and the increased metabolic clearance of LOS trough the pathways to other metabolites.
Pharmacologically, E3174 is approximately 10 to 40 times more potent as an angiotensin II blocker than LOS. In the volunteer study, no pharmacodynamic parameters (blood pressure and heart rate) were changed. However, when LOS and CYP2C9 inhibitors, such as BUC, phenylbutazone, sulfinpyrazone, and amiodarone, 16) are given concomitantly, the serum concentration of E3174 is decreased, theoretically leading to an apparently decreases the pharmacodynamic effects of LOS.
In conclusion, in the clinical situation, the drug interaction would be easy to find when the pharmacodynamics effect was exaggerated by coadministration with other drugs, while it may fail to be recognized when the pharmacodynamic effect was not obviously changed by the concomitant drugs. The drug interaction of LOS with bucolome is regarded as the latter case, and careful monitoring of the patients, who are taking LOS and bucolome or other CYP2C9 inhibitors simultaneously, would be needed on the potent that the drug interaction might cause a reduced therapeutic effect of LOS.
